Can Excision BioTherapeutics Inc Cure HIV?!

Excision BioTherapeutics, Inc. IND Application for EBT-101 for HIV Accepted by the US FDA

Excision BioTherapeutics, Inc., which focuses on developing CRISPR-based therapies intended to cure viral infectious diseases, announced that the U.S. FDA has accepted the firm’s Investigational New Drug (IND) application for EBT-101 – a CRISPR-based therapeutic candidate in development as a potential functional cure for chronic HIV.

The IND clearance enables Excision BioTherapeutics to initiate a first-in-human Phase 1/2 clinical trial to evaluate the safety, tolerability and efficacy of EBT-101 in individuals living with human immunodeficiency virus type 1 (HIV).

From the CEO of Excision BioTherapeutics

Leave a Reply